No Data
Truist Financial Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $180
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $140
Axsome Therapeutics Price Target Raised to $140 From $138 at RBC Capital
RBC Lifts Price Target on Axsome Therapeutics to $140 From $138, Keeps Outperform Rating
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Profit Outlook
Needham Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $133